+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Focal Segmental Glomerulosclerosis Market - Global Forecast 2025-2030- Product Image
Focal Segmental Glomerulosclerosis Market - Global Forecast 2025-2030- Product Image
Sale

Focal Segmental Glomerulosclerosis Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887513
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Focal Segmental Glomerulosclerosis (FSGS) market presents a complex yet rapidly advancing therapeutic landscape. Heightened clinical focus on targeted, patient-centric therapies, regulatory evolution, and global collaboration are reshaping opportunities for stakeholders seeking meaningful competitive differentiation.

Market Snapshot: Focal Segmental Glomerulosclerosis Market Opportunity

The focal segmental glomerulosclerosis market grew from USD 1.98 billion in 2024 to USD 2.13 billion in 2025. It is expected to continue growing at a CAGR of 7.87%, reaching USD 3.13 billion by 2030. This robust market trajectory is underpinned by increasing investment in precision therapies, evolving care models, and heightened global attention to unmet patient needs. Expanding portfolios and improved disease management underscore significant commercial potential for new entrants and established players alike.

Scope & Segmentation

This research provides a thorough analysis of the FSGS therapeutic arena, evaluating evolving treatment paradigms, global access patterns, and drivers of innovation across patient and care environments. The study covers segmentation by drug class, patient demographics, care delivery settings, and disease stage, alongside geographic regions and leading industry participants. The segmentation framework includes:

  • Drug Classes: Angiotensin Enzyme Inhibitors, Angiotensin Receptor Blockers, Corticosteroids
  • Disease Stages: Primary, Secondary
  • End-Use: Clinics, Hospitals
  • Patient Type: Adults, Pediatric
  • Regions: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Companies Tracked: Alkem Laboratories Ltd., Bristol Myers Squibb Company, Certa Therapeutics Pty Ltd., Cipla Ltd., CMG Biotech Pvt. Ltd., Dr Reddy's Laboratories Ltd., Fresenius Kabi Pvt. Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer, Inc., Sanofi S.A., Travere Therapeutics, Inc., Vera Therapeutics Inc.

Key Takeaways

  • Precision medicine approaches, such as biomarker-driven patient stratification, are redefining FSGS therapy selection and regulatory pathway opportunities.
  • Emergent therapies address a broader spectrum of disease mechanisms, moving beyond traditional supportive strategies to offer more individualized care solutions.
  • Digital health integration, including telemedicine and remote monitoring, is strengthening patient engagement while optimizing longitudinal outcome tracking.
  • Regional disparities in healthcare infrastructure and policy frameworks shape access to innovative treatments, highlighting the need for tailored launch and access strategies.
  • Corporate strategies increasingly emphasize partnerships, sustainable manufacturing, and value-based contracts to align with shifting payer expectations and regulatory trends.
  • Patient advocacy and co-designed clinical endpoints are influencing trial design, expediting recruitment, and ensuring real-world relevance in product development.

Tariff Impact: Navigating Policy Shifts and Supply Chain Resilience in FSGS Care

Recent changes in US trade tariffs have affected the FSGS supply chain, prompting organizations to realign raw material sourcing and manufacturing strategies. Nearshoring and vertical integration have gained traction to minimize disruption, while renegotiation of supplier agreements helps stabilize budgets for research and development. Distribution networks face new operational complexities and cost pressures, requiring coordination with payers to ensure continued therapy access for patients. Industry leaders are responding with regulatory advocacy and portfolio prioritization to safeguard late-stage programs and support uninterrupted treatment availability.

Market Methodology & Data Sources

This report leverages a mixed-methods approach, combining qualitative interviews with nephrology experts, payers, and advocacy leaders, and quantitative analysis from peer-reviewed literature, regulatory filings, and global treatment guidelines. Data triangulation and cross-validation ensure high confidence in findings and recommendations specific to the focal segmental glomerulosclerosis market.

Why This Report Matters

  • Enables strategic planning by providing actionable insights into market dynamics, evolving therapies, and shifting policy frameworks in FSGS care.
  • Supports informed investment and partnership decisions through robust segmentation, regional analysis, and strategic competitor benchmarking.
  • Drives superior patient outcomes by guiding development and market access strategies rooted in real-world stakeholder priorities.

Conclusion

The FSGS market is undergoing rapid transformation, fueled by innovation, supply chain adaptation, and stakeholder engagement. Informed strategy and collaborative partnerships will be vital for those seeking to drive improved patient care and sustainable growth in this evolving therapeutic space.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in precision medicine with biomarker-driven FSGS patient stratification for targeted therapies
5.2. Rising investment in gene editing technologies focusing on APOL1 gene variants associated with FSGS susceptibility
5.3. Development of novel endothelin receptor antagonists demonstrating nephroprotective effects in FSGS clinical studies
5.4. Expansion of patient-centric digital health platforms for remote monitoring and management of FSGS progression
5.5. Increasing collaboration between academia and biotech firms to accelerate early-stage FSGS drug discovery pipelines
5.6. Growing prevalence of FSGS in paediatric populations driving demand for age-specific therapeutic formulations
5.7. Emergence of real-world evidence studies to validate long-term safety and efficacy of emerging FSGS treatments
5.8. FDA breakthrough therapy designations accelerating regulatory paths for innovative FSGS biologics and small molecules
5.9. Adoption of liposomal drug delivery systems to enhance renal targeting and reduce off-target toxicity in FSGS therapies
5.10. Surge in strategic partnerships between CROs and pharma companies for FSGS clinical trial optimization
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Focal Segmental Glomerulosclerosis Market, by Drug Class
8.1. Introduction
8.2. Angiotensin Enzyme Inhibitors
8.3. Angiotensin Receptor Blockers
8.4. Corticosteroids
9. Focal Segmental Glomerulosclerosis Market, by Stage
9.1. Introduction
9.2. Primary
9.3. Secondary
10. Focal Segmental Glomerulosclerosis Market, by End-Use
10.1. Introduction
10.2. Clinics
10.3. Hospitals
11. Focal Segmental Glomerulosclerosis Market, by Patient Type
11.1. Introduction
11.2. Adults
11.3. Pediatric
12. Americas Focal Segmental Glomerulosclerosis Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Focal Segmental Glomerulosclerosis Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Focal Segmental Glomerulosclerosis Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alkem Laboratories Ltd.
15.3.2. Bristol Myers Squibb Company
15.3.3. Certa Therapeutics Pty Ltd.
15.3.4. Cipla Ltd.
15.3.5. CMG Biotech Pvt. Ltd.
15.3.6. Dr Reddy's Laboratories Ltd.
15.3.7. Fresenius Kabi Pvt. Ltd.
15.3.8. GSK PLC
15.3.9. Hikma Pharmaceuticals PLC
15.3.10. Intas Pharmaceuticals Ltd.
15.3.11. Lupin Ltd.
15.3.12. Merck & Co., Inc.
15.3.13. Novartis AG
15.3.14. Otsuka Pharmaceutical Co., Ltd
15.3.15. Pfizer, Inc.
15.3.16. Sanofi S.A.
15.3.17. Travere Therapeutics, Inc.
15.3.18. Vera Therapeutics Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET: RESEARCHAI
FIGURE 24. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET: RESEARCHSTATISTICS
FIGURE 25. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET: RESEARCHCONTACTS
FIGURE 26. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 36. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 37. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 38. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 39. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 40. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 45. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 46. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 47. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 48. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 49. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 50. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 51. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 52. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 55. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 56. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 57. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 58. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 59. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 60. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 61. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 62. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 63. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 64. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 65. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 66. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 67. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 68. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 69. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 70. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 71. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 72. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 73. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 74. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 75. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 76. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 77. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 78. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 79. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 80. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 81. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 82. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 83. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 84. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 85. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 86. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 98. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 100. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 102. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 105. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 108. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 109. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 110. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 111. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 116. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 117. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 118. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 119. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 122. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 123. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 124. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 125. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 126. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 127. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 128. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 129. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 132. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 133. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 134. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 135. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 140. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 141. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 142. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 143. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 144. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 156. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 158. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 164. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 166. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 172. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 173. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 174. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 175. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 176. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 177. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 178. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 179. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 180. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 181. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 182. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 183. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 188. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 189. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 190. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 191. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 196. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 197. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 198. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 199. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 204. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 205. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 206. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 207. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 210. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 211. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 212. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 213. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 214. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 215. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 220. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 221. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 222. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 223. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 228. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 229. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 230. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 231. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 233. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 236. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 237. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 238. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 239. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 240. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 241. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 244. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 245. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 246. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 247. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 252. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 253. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 254. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 255. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 260. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 261. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 262. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 263. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 268. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 270. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 275. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 278. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 279. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 280. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 281. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 282. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 283. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 286. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 287. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 288. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 289. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 291. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 292. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 293. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 294. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 295. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 296. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 297. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 298. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 299. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 302. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 303. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
TABLE 304. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2030 (USD MILLION)
TABLE 305. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 306. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 307. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Focal Segmental Glomerulosclerosis market report include:
  • Alkem Laboratories Ltd.
  • Bristol Myers Squibb Company
  • Certa Therapeutics Pty Ltd.
  • Cipla Ltd.
  • CMG Biotech Pvt. Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Fresenius Kabi Pvt. Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer, Inc.
  • Sanofi S.A.
  • Travere Therapeutics, Inc.
  • Vera Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.13 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Focal Segmental Glomerulosclerosis Global Market Report 2025 - Product Image

Focal Segmental Glomerulosclerosis Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Focal Segmental Glomerulosclerosis - Pipeline Insight, 2025 - Product Image

Focal Segmental Glomerulosclerosis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Focal Segmental Glomerulosclerosis Drugs Market Report 2025 - Product Image

Focal Segmental Glomerulosclerosis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Focal Segmental Glomerulosclerosis - Global Strategic Business Report - Product Image

Focal Segmental Glomerulosclerosis - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2034 - Product Image

Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2034

  • Report
  • 92 Pages
  • Global
From

About the Focal Segmental Glomerulosclerosis Market

Focal Segmental Glomerulosclerosis (FSGS) is a type of kidney disorder that affects the filtering units of the kidney, known as glomeruli. It is a leading cause of nephrotic syndrome, a condition characterized by proteinuria, edema, and hypoalbuminemia. FSGS is a major cause of end-stage renal disease (ESRD) and is associated with a high risk of progression to ESRD. Treatment of FSGS is focused on controlling the underlying cause, if possible, and managing the symptoms. Treatment options include medications, lifestyle modifications, and dialysis. The market for Liver and Kidney Disorders Drugs is expected to grow in the coming years due to the increasing prevalence of chronic kidney diseases and liver diseases. The market is driven by factors such as the increasing prevalence of diabetes, rising geriatric population, and the increasing demand for organ transplants. Companies in the Focal Segmental Glomerulosclerosis market include AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.